ALSEN (ALSEN) News
Follow ALSEN (ALSEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Sensorion (ALSEN) Reports H1 2026 Results; Cash €88M, Funds Into 2027
Sensorion reported H1 2026 results: cash and short-term deposits €88M, net loss €20.7M. Company says funding runway extends to end-2027 and ANSM authorized the Phase I/II HearConnex trial for SENS-601 in France; first do
EARNINGS | Sep 23, 2026, 05:30 AM UTC
L
Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:Sensorion (FR001401A9Z0 — ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, to
NEWS | Sep 23, 2026, 05:30 AM UTC
L
Sensorion Announces the Completion of Its Reverse Share Split
Regulatory News:Sensorion (FR001401A9Z0 — ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders,
EQUITY | Sep 15, 2026, 05:30 AM UTC
L
Sensorion Announces The Completion Of Its Reverse Share Split >ALSEN.FR
Sensorion Announces The Completion Of Its Reverse Share Split >ALSEN.FR
NEWS | Sep 15, 2026, 05:30 AM UTC
M
Sensorion receives ANSM authorization to start SENS-601 trial in France
Sensorion said the ANSM has authorized it to initiate its Hear… clinical trial in France for SENS-601, its investigational gene therapy for GJB2-related hearing loss.
EQUITY | Sep 03, 2026, 05:30 AM UTC